secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0000950170-24-022060
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools FY2023 revenue $106M (+9%); Q4 gross margin 59.6%; SomaLogic merger closed
--------------------------------------------------------------------------------

- FY2023 revenue $106.3M (+9% YoY); Q4 revenue $28.2M (+4%); instrument sales +46% for FY.
- Non-GAAP gross margin 60.1% for FY2023 (+900 bps YoY); net loss $74.7M.
- Non-GAAP adjusted EBITDA loss improved $34M to $34.7M; operating cash use down 53%.
- Combined pro forma 2023 revenue ~$192M; pro forma cash $565M (incl. SomaLogic's $449.8M).
- Merger with SomaLogic closed Jan 5, 2024; integration underway; CEO cites disciplined execution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000095017024022060/0000950170-24-022060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000095017024022060/lab-20240228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-022060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer